Table 3. Increase in CTCAE grade and prevalence of high-risk patients.
|
Change in CTCAE Grade after start of therapy |
QTc⩾470 |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| TKI | N | ΔQTc⩾30 ms N (%) | Increased N (%) | Unchanged N (%) | Reduced N (%) | P-value | Baseline N (%) | Therapy N (%) | P-value |
| Whole | 363 | 76 (20.9) | 33 (9.1) | 321 (88.4) | 9 (2.5) | 0.0003 | 6 (1.7) | 21 (5.8) | 0.005 |
| Sunitinib | 110 | 22 (20.0) | 4 (3.6) | 104 (95.6) | 2 (1.8) | 0.746 | 1 (0.9) | 3 (2.7) | 0.617 |
| Vemurafenib | 67 | 23 (34.3) | 9 (13.4) | 58 (86.6) | 0 (0) | 0.008 | 1 (1.5) | 8 (11.9) | 0.023 |
| Sorafenib | 52 | 11 (21.2) | 6 (11.6) | 45 (86.6) | 1 (1.9) | 0.073 | 1 (1.9) | 2 (3.9) | 1 |
| Pazopanib | 46 | 6 (13.0) | 3 (6.5) | 41 (89.1) | 2 (4.4) | 0.410 | 1 (2.2) | 2 (4.4) | 1 |
| Imatinib | 41 | 8 (19.5) | 5 (12.2) | 34 (82.9) | 2 (4.9) | 0.430 | 1 (2.4) | 1 (2.4) | 1 |
| Erlotinib | 21 | 3 (14.3) | 3 (14.3) | 18 (85.7) | 0 (0) | 0.174 | 0 (0) | 2 (9.5) | NA |
| Lapatinib | 16 | 1 (6.3) | 1 (6.3) | 14 (87.5) | 1 (6.3) | 1 | 1 (6.3) | 1 (6.3) | 1 |
| Gefitinib | 10 | 2 (20.0) | 2 (20.0) | 7 (70.0) | 1 (10.0) | 0.423 | 0 (0) | 2 (20.0) | NA |
Abbreviations: CTCAE=common terminology criteria for adverse events; N=number of patients; NA=not applicable; TKI=tyrosine kinase inhibitor; ΔQTc=difference between QTc interval during TKI treatment and QTc interval at baseline measurement. Bold values are statistically significant.